Standard Pricing

Time Remaining
2022 New Zealand Melanoma Summit

Achieving consistent, best practice melanoma care through collaborative action

Kia ora koutou,

We are delighted to invite you to attend the postponed New Zealand Melanoma Summit from 11 - 13 February 2022 at the University of Auckland, Auckland.

New Zealand continues to have one of the highest incidence rates of melanoma in the world. By attending the Summit you will be joining over 200 health professionals who are passionate about reducing the incidence and impact of melanoma in New Zealand.

Organised by the Melanoma Network of New Zealand Incorporated (MelNet), the sixth New Zealand Melanoma Summit will examine and discuss recent developments in melanoma management and identify priorities for action for New Zealand. It will provide you an opportunity to exchange ideas and practices, and develop friendships and professional linkages with other delegates and agencies. Mostly importantly, the Summit will formally launch the long awaited 'Quality Statements for Melanoma Care in New Zealand' which will guide quality melanoma care in New Zealand. 

The Summit programme will feature a diverse range of experts recognised internationally for their contribution to melanoma management. There will be engaging presentations, interactive panel discussions as well as workshops on prevention, diagnosis, treatment and research.

We look forward to meeting you in February.

Dr Chris Boberg and Mr Gary Duncan

MelNet Executive Committee Co-Chairs

  • 14 Hrs RNZCGP CME Approved
2022 New Zealand Melanoma Summit

Keynote Speakers

Professor David Whiteman

Keynote Speaker

Senior Scientist and Deputy Director, QIMR Berghofer Medical Research Institute, Queensland, Australia

Professor Cliff Rosendahl

Keynote Speaker

Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia

Adjunct Associate Professor Amanda Oakley

Keynote Speaker

Dermatologist
Waikato District Health Board

Professor Grant McArthur

Keynote Speaker

Head Molecular Oncology Laboratory, Peter MacCallum Cancer Centre and Executive
Director, Victoria Comprehensive Cancer Centre, Melbourne, Australia

Dr Inês Pires da Silva

Keynote Speaker

Medical Oncologist and Researcher Scientist at Melanoma Institute Australia, Westmead and Blacktown Hospitals, and The University of Sydney

Associate Professor Louisa Gordon

Keynote Speaker

Group Leader Health Economics, QIMR Berghofer Medical Research Institute

Dr Mark Faries

Keynote Speaker

Professor of Surgery and Co-Director Cutaneous Oncology Program, The Angeles Clinic and Research Institute and Cedars-Sinai Medical Center, Los Angeles, USA

2022 New Zealand Melanoma Summit

Draft Programme

  • Pre-conference Workshop Optional Workshop - Friday - 11 February 2022
  • Day 1 Saturday - 12 February 2022
  • Day 2 Sunday - 13 February 2022
9:00 AM
---
10:15 AM
Professor Cliff Rosendahl

Chaos and Clues and Prediction without Pigment Refresher: A Case Based Approach (CR)

Professor Cliff Rosendahl will give a summary of the Chaos and Clues and the Prediction without Pigment algorithms for pigmented and non pigmented skin lesions. He will illustrate the use of these algorithms with different cases. He will cover exceptions to algorithms, the common pitfalls, common mistakes and tips on diagnosing seborrheic keratosis.
10:45 AM
---
11:15 AM
Associate Professor Amanda Oakley

Skin lesion referrals and photography (AO)

Associate Professor Amanda Oakley will discuss the finer points on referrals for skin lesions. She will also give a primer on practical photography for clinical and dermatoscopic photos.
11:15 AM
---
11:45 AM
Associate Professor Amanda Oakley

Sequential dermatoscopy (AO)

Associate Professor Amanda Oakley will discuss sequential dermatoscopy. Professor Oakley has had many years of experience in sequential dermatoscopy via her work with Molemap. She would share with you her indications for sequential dermatoscopy and the definition of 'significant' dermatoscopic change (which can vary depending on the patient's age and the time between sequential dermatoscopic photos). She will also touch on the medico-legal aspects of having a sequential dermatoscopy system for your practice.
11:45 AM
---
12:45 PM
Professor Cliff Rosendahl

Facial nonpigmented and pigmented skin lesions (CR)

Professor Cliff Rosendahl will, using a case based approach discuss the diagnosis of facial lesions both pigmented and non-pigmented. He will discuss how to tackle these difficult dermatoscopic problems in a simplified way. He will also discuss how a flat, pigmented lesion on the face is unlikely to be a naevus.
3:00 PM
---
3:45 PM
Professor Cliff Rosendahl

Non-pigmented skin lesions (CR)

Non-pigmented skin lesions have less specific clues to diagnosis. However, sometimes medical-legally, it is helpful to give a more confident diagnosis on difficult to classify non-pigmented skin lesions. Professor Cliff Rosendahl will review the use of Revised Pattern Analysis to help diagnose non-pigmented skin lesions and will develop a method to deal with them practically.
3:45 PM
---
4:15 PM
Professor Cliff Rosendahl

Virtual Patient Quiz – Atypical Naevi (CR)

Patients with many atypical naevi are at higher risk of melanoma however their management can be complex and difficult as many of their lesions all look unusual. Professor Cliff Rosendahl will go through multiple cases of patients with lots of atypical naevi and provide a practical approach to determine benign from malignant lesions - all in an interactive quiz.
4:15 PM
---
4:45 PM
Professor Amanda Oakley

Final Quiz (AO)

Professor Amanda Oakley will make a quiz to test the knowledge learnt from this highly practical course.
8:00 am
---
9:20 am

Opening session

Opening address
Guest speaker

2021 Melanoma Summit overview
Dr Chris Boberg, Chair 2021 New Zealand Melanoma Summit Planning Committee and Co-Chair, MelNet

Patient challenge
Terence Walsh, Patient representative

Melanoma in the New Zealand cancer landscape
Professor Diana Sarfati, National Director of Cancer Control and Chief Executive, Te Aho o Te Kahu - Cancer Control Agency

Quality Statements for to Guide Melanoma Diagnosis and Treatment in New Zealand
Dr Richard Martin, Surgical Oncologist, New Zealand Melanoma Unit, Waitemata District Health Board and Chair Melanoma Quality Statements Working Group

9:20 am
---
10:30 am

Session 1: Epidemiology and primary prevention

Epidemiological trends in melanoma
Professor David Whiteman, Deputy Director, Head of Cancer Control Laboratory and Coordinator, Melanoma and Skin Cancer Research Centre, QIMR Berghofer Medical Research Institute, Queensland, Australia

What is happening about sunscreens in New Zealand?
Jon Duffy, Chief Executive, Consumer New Zealand
Dr Louise Reiche, Dermatologist, Kauri Healthcare Palmerston North and Immediate Past President, New Zealand Dermatological Society Incorporated 

My story
Todd Muller, Patient representative

Questions and discussion
11.00 am
---
12.00 noon

Session 2: Early detection

Early detection saves lives: Our story
Chris and Judy Bailey, Patient representatives

The evolution of early detection, dermatoscopy and artificial intelligence
Professor Cliff Rosendahl, Course Coordinator of the Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
Adjunct Associate Professor Amanda Oakley, Dermatologist, Waikato District Health Board

Questions and discussion
12.00 noon
---
12:30 pm

Session 3: Controversy of borderline lesions

Clinico-histological collaboration
Professor Cliff Rosendahl, Course Coordinator of Master of Medicine (Skin Cancer) Programme, University of Queensland, Australia
Dr Ben Tallon, Dermatologist, SKIN Dermatology Institute and Dermatopathologist, Pathlab, Tauranga
Dr Richard Massey, Pathologist and Director, Pathology Associates, Tauranga
Dr Michael Hitchcock, Pathologist and Clinical Lead, Anatomic Pathology Services, Auckland District Health Board

Questions and discussion

1:30 pm
---
2:45 pm

Session 4: Concurrent breakout session 1

Breakout 4A - New Zealand primary prevention and early detection initiatives
This session will highlight and discuss primary prevention and early detection initiatives underway in the sector. It will also discuss the New Zealand Skin Cancer Primary Prevention and Early Detection Strategy and its alignment with the Te Aho o te Kahu – Cancer Control Agency ‘Prevention Strategies’ report.

Breakout 4B - Dermatoscopy in action
In this session Professor Cliff Rosendahl will teach the basics of the ‘chaos and clues’ approach to dermatoscopy in diagnosing melanoma and will demonstrate its practical application to specific cases.

Breakout 4C - MelNet melanoma multi-disciplinary meeting: challenging cases
In this session, a multi-disciplinary panel will discuss the clinical management of a range of challenging or unusual cases of melanoma.

Breakout 4D - Upcoming research and innovations
Presenters whose submitted abstracts have been selected will provide snapshots of upcoming research and clinical innovations
3:15 pm
---
4:15 pm

Session 5: Paving the way for high quality, collaborative melanoma care

Waitemata District Health Board: a collaborative skin cancer care model
Dr Daniel Wen, House Officer, Waitemata District Health Board

Nurse led dermatoscopy clinics: the way of the future?
Katy Doherty, Managing Director, Espy Skin, Auckland
Trish Baker, Managing Director, Healthbox NZ Ltd, Auckland

Serious Illness Conversation Guide
Jane Goodwin, Advance Care Planning Facilitator, Health Quality and Safety Commission and Registered Nurse, Canterbury District Health Board

4.15 pm
---
5.00 pm

Session 6: Concurrent breakout session 2

Breakout 6A - Pathology synoptic reporting and histology updatee
This session will update on progress towards consistent synoptic reporting for skin cancer.

Breakout 6B - New Zealand melanoma research and therapy special interest group
Intended for those involved or interested in being part of the Melanoma Research and Therapy Special Interest or those with an interest in research or therapy.

Breakout 6C - Serious Illness Conversation Guide
Using the Serious Illness Conversation Guide, this session will build on the plenary session to help develop skills and confidence in having difficult conversations with patients and their whanau.

Breakout 6D - GPs with a special interest in skin cancer
Intended for those who are part of or interested in joining New Zealand Skin Cancer Doctors. The session will provide an overview of New Zealand Skin Cancer Doctors and the work they do. It will also include a discussion of interesting dermatoscopic and surgical cases. Attendees are encouraged to bring along cases to discuss.
5.00 pm
---
5.15 pm

Session 7: Day one wrap up

Highlights and recommendations from breakout sessions and day one summary
5:15 pm
---
5:30 pm
5:30 pm
---
7:30 pm
8:00 am
---
9:30 am

Session 8: State of the art melanoma management

My story Dr Jeff Dalley, Patient representative

In situ melanoma - current best practice in New Zealand Dr Andrew MacGill, Director, SkinCheck Northcote, Auckland and fully accredited member of New Zealand Skin Cancer Doctors Society 

Mohs surgery for melanoma Dr Paul Salmon, Dermatologist, Skin Centre Tauranga and Auckland Dermatology

The current role of sentinel node biopsy in managing primary melanoma Dr Mark Faries, Professor of Surgery and Co-Director Cutaneous Oncology Program, The Angeles Clinic and Research Institute and Cedars-Sinai Medical Center, Los Angeles, USA

Questions and discussion
10:00 am
---
12:00 noon

Session 9: Advanced melanoma management

My story
Tim Stevens, Patient representative

The future and evolution of adjuvant and neoadjuvant therapy
Dr Inês Pires da Silva, Medical Oncologist and Researcher Scientist at Melanoma Institute Australia, Westmead and Blacktown Hospitals, and University of Sydney

The New Zealand situation
Dr Jody Jordan, Medical Oncologist, Hawke’s Bay District Health Board and Canopy Cancer Care, Hastings

Nurses care perspective on managing advanced melanoma
Jo Tuaine, Oncology Clinical Nurse Specialist, Southern Blood and Cancer Service, Southern District Health Board

Questions and discussion
1:00 pm
---
1:40 pm

Session 10: Melanoma and genetics

Current status of molecular profiling of melanoma
Professor Grant McArthur, Head Molecular Oncology Laboratory, Peter MacCallum Cancer Centre and Executive Director, Victoria Comprehensive Cancer Centre, Melbourne, Australia

Questions and discussion
1:40 pm
---
2:30 pm

Session 11: The economics of the skin cancer epidemic

Escalating the economic burden of skin cancer to Government
Associate Professor Louisa Gordon, Group Leader Health Economics, QIMR Berghofer Medical Research Institute

The private sector
Dr Stephen Child, Chief Medical Officer, Southern Cross

Questions and discussion  

2:30 pm
---
3:15 pm

Session 12: Concurrent breakout session 3

Breakout 12A - Priorities for action – primary prevention
This session will workshop priorities for action for New Zealand that support primary prevention.

Breakout 12B - Priorities for action – early detection
This session will workshop priorities for action for New Zealand that support early detection.

Breakout 12C - Priorities for action – clinical management of advanced disease and research
This session will workshop priorities for action for New Zealand relating to the clinical management of advanced disease and research.
3:45 pm
---
5:00 pm

Session 13: Looking to the future of melanoma

Setting the priorities for action - recommendations from concurrent breakout session 3

Panel: The future of melanoma prevention, diagnosis, treatment, care and research

Patient perspective - the final say

Wrap up, recommendations and closing remarks
2022 New Zealand Melanoma Summit

Testimonials

2022 New Zealand Melanoma Summit

Get Your Tickets

Standard registration until 7 January
$5192 DAYS
  • Full 2 Day Conference(Includes coffee, lunch, tea, conference networking function on Friday)
  • Scientists, nurses, registrars, health promoters, allied health professionalsSubsidised price
  • RNZCGP Endorsed eventThe 2021 New Zealand Melanoma Summit activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 14 CME credits for Continuing Professional Development (CPD) purposes.
LEARN MORE
GST inclusive
Standard registration until 7 January
$8192 DAYS
  • Full 2 Day Conference(Includes coffee, lunch, tea, conference networking function on Friday)
  • Medical doctorsFull price
  • RNZCGP Endorsed eventThe 2021 New Zealand Melanoma Summit activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 14 CME credits for Continuing Professional Development (CPD) purposes.
LEARN MORE
GST inclusive
Standard registration until 7 January
$16953 DAYS
  • Full 2 day Conference + Certificate of Fundamental Dermatoscopy with Professors Cliff Rosendahl and Amanda Oakley(Includes coffee, lunch, tea, conference networking function on Friday)
  • Includes Molescope 2 Dermatoscope (value $445)Subsidised prices for registrars and nurses at $1545
  • RNZCGP Endorsed eventThe 2021 New Zealand Melanoma Summit and the Certificate of Fundamental Dermatoscopy activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 26 CME credits for Continuing Professional Development (CPD) purposes.
LEARN MORE
GST inclusive

Our Sponsors:

 

  

.